Home  /   Products  /   Painkillers  /   Etoricoxib (Etaria) 60 mg – [28 tablets]

Etoricoxib (Etaria) 60 mg – [28 tablets]


Non-steroidal anti-inflammatory drugs (nsaids)

SKU: 63458 Category:


Etaria tablets is a type of NSAID (non-steroidal anti-inflammatory drug) used to treat a variety of conditions, from mild to moderate pain to inflammation. Etaria tablets are available in a variety of strengths and are used to treat pain and inflammation associated with osteoarthritis, rheumatoid arthritis, gout, and ankylosing spondylitis.
Etaria (Etoricoxib) Pharmacodynamics
Etaria tablets containing Etoricoxib is a selective inhibitor of cyclooxygenase-2 (COX-2), in therapeutic concentrations it blocks formation of prostaglandins and has anti-inflammatory, analgesic and antipyretic effects. Selective inhibition of COX-2 by etoricoxib is accompanied by a decrease in the severity of clinical symptoms associated with inflammation, while there is no effect on platelet function and the mucosa of the gastrointestinal tract. Etoricoxib has a dose-dependent COX-2 inhibitory effect, with no effect on COX-1 at a daily dose of up to 150 mg. The drug has no effect on the production of prostaglandins in the gastric mucosa and bleeding time. No reduction in arachidonic acid and collagen-induced platelet aggregation was observed in the studies conducted.
Indications for Etaria tablets
  • Symptomatic therapy of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, pain and inflammatory symptoms associated with acute gouty arthritis.
  • Therapy of moderate to severe acute pain after dental surgery.
  • Hypersensitivity to any component of the drug;
  • Complete or incomplete combination of bronchial asthma, recurrent nasal or paranasal sinus polyposis and intolerance to acetylsalicylic acid and other NSAIDs (including history);
  • erosive-ulcerative changes of the mucosa of the stomach or duodenum, active gastrointestinal bleeding; cerebrovascular or other bleeding;
  • inflammatory bowel disease (Crohn’s disease, non-specific ulcerative colitis) in the acute phase;
  • hemophilia and other blood clotting disorders;
  • Severe heart failure (II-IV functional class according to NYHA);
  • Severe hepatic insufficiency (more than 9 points on the Child-Pugh scale) or active liver disease;
  • severe renal insufficiency (creatinine clearance less than 30 ml/min), advanced renal disease, confirmed hyperkalemia;
  • period after coronary artery bypass grafting; peripheral artery disease, cerebrovascular disease, clinically evident coronary heart disease;
  • persistent blood pressure values exceeding 140/90 mm Hg in uncontrolled arterial hypertension;
  • Pregnancy, breast-feeding;
  • children under 16 years of age.
Dosage and administration method
  • Orally, with a small amount of water and regardless of meals.
  • The recommended dose is 60 mg once a day. Rheumatoid arthritis and ankylosing spondylitis: The recommended dose is 90 mg once a day.
  • The recommended dose in the acute period is 120 mg once a day. The duration of use of the drug in a dose of 120 mg should not exceed 8 days. The minimum effective dose should be used for the shortest possible course.
  • The average therapeutic dose for pain syndrome is 60 mg once a day. Acute pain after dental surgery:
  • The recommended dose is 90 mg once daily. In the treatment of acute pain the drug ETARIA should be used only in the acute period, limited to a duration of not more than 8 days.
  • The daily dose for pain relief after dental surgery should not exceed 90 mg.